Anti-Cancer Liposomes


Authors : Mahira Amirova; Ellada Huseynova; Gulnara Vahabova; Rena Rahimova; Gulnara Dashdamirova

Volume/Issue : Volume 7 - 2022, Issue 3 - March

Google Scholar : http://bitly.ws/gu88

Scribd : https://bit.ly/3ilnyxU

DOI : https://doi.org/10.5281/zenodo.6372349

Tumor is one of the most wide-spread diseases across the planet, and along with this - the first in a row of the working-age population death causes. The pathogenesis of uncontrolled tissue growth and malignancy is still unexplored, making the tumor one of the most difficult, if not curable, diseases to treat. Tumor treatment today is carried out by extremely undesirable methods, the leading role among which belongs to chemoand radiation therapy, the result of which is always inevitable - death. In this regard, there is an urgent need to find medicines that can save the lives hundreds of thousands of people without causing tangible harm to the body. Such drugs can be liposomes, which have long attracted the attention of scientists in the framework of the neoplasia treatment, but still remain at the research stage due to the high cost and complexity of industrial production.Using the data, accumulated to date on liposomes and their invasiveness in tumor tissue, we propose our own version of liposome production, which, due to its relatively low toxicity and ease of manufacture, has more chances of being introduced into widespread medical practice: these are liposomes based on the liquid phase from Chaga fungus and the lipid phase with natural peptides relatively easily extracted from plants and microorganisms.

Keywords : liposome, natural peptides, neoplasia

CALL FOR PAPERS


Paper Submission Last Date
31 - July - 2022

Paper Review Notification
In 1-2 Days

Paper Publishing
In 2-3 Days

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe